Skip to main content

Table 1 Trends of annual antibacterial consumption during the entire study period

From: Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019

Antimicrobial class

Annual consumption of antibiotics(DDDs/1000 patient-days)

Linear regression

2012

2013

2014

2015

2016

2017

2018

2019

P

Trend

Tetracyclines

0.71

0.06

2.87

4.07

2.49

5.28

5.08

6.78

0.001

Increasing

Amphenicols

1.06

0.91

0.76

0.44

0.49

0.57

0.53

0.45

0.009

Decreasing

Penicillins (except for P/BLI combinations)

26.98

16.46

14.85

10.06

11.85

10.79

12.24

13.84

0.072

No statistically significant difference

BL/BLI combinations

73.09

63.88

90.08

122.26

149.85

176.25

179.49

197.33

0.000

Increasing

P/BLI combinations

57.47

42.74

63.39

89.29

111.45

143.94

145.26

165.17

0.000

Increasing

C/BLI combinations

15.62

21.14

26.69

32.97

38.40

32.31

34.24

32.17

0.020

Increasing

Cephalosporins (except for C/BLI combinations)

200.71

208.67

169.56

170.48

182.50

157.53

126.69

121.53

0.001

Decreasing

First-generation

31.01

23.33

18.97

14.49

13.58

10.72

9.05

8.86

0.000

Decreasing

Second-generation

84.40

99.06

98.36

97.53

105.56

80.33

71.46

74.49

0.135

No statistically significant difference

Third-generation

85.30

86.27

52.23

58.46

63.35

66.47

46.17

38.18

0.013

Decreasing

Carbapenems

3.09

3.97

7.20

11.55

16.34

22.93

19.23

23.84

0.000

Increasing

imipenem

1.72

1.58

2.91

3.76

4.16

4.64

3.47

4.46

0.008

Increasing

meropenem

1.37

2.39

4.29

7.79

12.15

16.71

13.58

16.13

0.000

Increasing

biapenem

0

0

0

0

0.02

1.59

2.19

3.25

0.015

Increasing

Macrolides

26.84

38.66

45.00

45.19

40.44

38.58

26.82

30.11

0.580

No statistically significant difference

Lincosamides

16.09

9.00

0.58

0.63

0.68

0.43

0.22

0.24

0.027

Decreasing

Aminoglycosides

10.52

9.63

11.98

9.08

9.11

8.56

6.94

9.15

0.072

No statistically significant difference

Quinolones

100.35

81.53

90.38

91.47

112.51

108.03

63.12

54.02

0.225

No statistically significant difference

  1. BL/BLI β-lactam/β-lactamase inhibitor, C/BLI cephalosporin/β-lactamase inhibitor, P/BLI penicillin/β-Lactamase inhibitor
  2. Annual consumption of antibiotics was expressed in defined daily doses (DDDs)/1000 patient-days for various antibiotic classes
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us